Tolga KÖŞECİ, Ümit KARABULUT, Bünyamin SARITAŞ, Serkan YARAŞ, Fehmi ATEŞ, Engin Altintaş Orhan SEZGİN, Orhan SEZGİN

Ornidazol’e bağlı karaciğer toksisitesi: İki olgu sunumu

Ornidazol günlük uygulamalarda sık kullanılan, nitroimidazol türevi antibiyotiklerdendir. Ornidazole bağlı toksik hepatit nadir olarak görülmekte olup fakat ciddi sonuçları olabilen bir durumdur. Akut karaciğer hasarı ilaca bağlı karaciğer hasarının en sık görülen biçimidir ve akut hepatitilerin %10'luk kısmını oluşturur. Kliniğimizde ornidazol kullanımına ikincil toksik hepatit tanısı koyduğumuz iki olguyu sunuyoruz.

Anahtar Kelimeler:

Ornidazol, toksik hepatit

Ornidazole-induced liver toxicity: Report of two cases

Ornidazole is one of the nitroimidazole-derivative antibiotics and is often used in daily practice. Hepatotoxicity caused by ornidazole is rare, but when it occurs, it can have serious results. Acute liver injury is the most common type of drug-induced hepatitis and accounts for 10% of acute hepatitis. Here, we report two cases of drug-induced hepatitis caused by ornidazole.

Keywords:

Ornidazole, toxic hepatitis,

PDF

___

Koch-Weser J, Goldman P. Drug therapy: metronidazole. N Engl J Med 1980;303:1212-8.
Koflar Y, fiaflmaz N, O¤uz P, et al. Ornidazole-induced autoimmu ne hepatitis. Eur J Gastroenterol Hepatol 2001;13:737-9.
Ersöz G, Karasu Z, Akarca US, et al. Nitroimidazole-induced chronic hepatitis. Eur J Gastroenterol Hepatol 2001;13:963-6.
Tabak F, Özaras R, Erzin Y, et al. Ornidazole induce liver damage: report of three cases and review of the literature. Liver International 2003:23:351-4.
Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepa tic injuries: a French population-based study. Hepatology 2002;36:451-5.
Shapiro MA, Lewis JH. Causality assessment of drug-induced hepa totoxicity: promises and pitfalls. Clin Liver Dis 2007;11:477-505.
Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992;232:133-8.
Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. N Z Med J 1996;109:315-9.
Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002;22:145-55.
Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:192434.
Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced li ver injury. Semin Liver Dis 2009;29:337-47.
Chang CY, Schiano TD. Review article: drug hepatotoxicity. Ali ment Pharmacol Ther 2007;25:1135-51.
Björnsson E. Drug-induced liver injury: Hy's rule revisited. Clin Phar macol Ther 2006;79:521-8.
Reuben A. Hy's law. Hepatology 2004; 39:574-8.
Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000;4:73-96.
Benichou C. Criteria of drug-induced liver disorders.Report of an In ternational Consensus Meeting. J Hepatol1990;11:272-6.
Gearhart M O. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994;28:1177-81.
Garcia Rodriguez L A, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999;48:847-52.
Hay RJ. Risk/benefit ratio of modern antifungal therapy. Focus on hepatic reactions. J Am Acad Dermatol 1993;29:S50-4
Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997;25:103-7.